Walters, M. C., Tisdale, J. F., Mapara, M. Y., Krishnamurti, L., Kwiatkowski, J. L., Aygun, B., Kasow, K. A., Rifkin-Zenenberg, S., Jaroscak, J., Garbinsky, D., Chirila, C., Gallagher, M. E., Zhang, X., Ho, P.-R., Thompson, A. A., & Kanter, J. (2021). Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood, 138(Supplement 1), 7–7. https://doi.org/10.1182/blood-2021-146905